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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States.
Patients with COPD often suffer from various co-morbidities, such as cardiovascular disease, osteoporosis, cachexia and
anaemia, which are a consequence of systemic inflammation. The co-morbidities of COPD are believed to be associated
with a more severe course of the underlying disease and with a poorer prognosis. It is being disputed whether
extrapulmonary co-morbidities or respiratory complications are the main cause of mortality in patients with COPD. The
aim of the study was to analyse the causes of death and co-morbidities in COPD patients who had died during hospitalisa-
tion at the Department of Internal Medicine, Pneumonology and Allergy, Medical University of Warsaw, Poland, between
2004 and 2008.
Material and methods: We analysed 266 consecutive medical records of COPD patients who had died during hospitalisa-
tion. They included 179 men (67%) and 87 women (33%). The mean age at death was 73 ± 8 years (women: 74 ± 9 years).
Results: The causes of death in the analysed group of patients included: acute exacerbation of COPD (n = 81 [81%]; 49 men
and 32 women), pneumonia (n = 67 [25%]; 50 men and 17 women), lung cancer (n = 50 [19%]; 32 men and 18 women),
ischaemic heart disease (n = 20 [7%]; 15 men and 5 women), heart failure (n = 14 [5%]; 8 men and 6 women) and other
causes (n = 34 [14%]). Most of the deaths from lung cancer were observed among younger patients (p = 0.002), while
most of the deaths from pneumonia among older patients (p = 0.02). The most common co-morbidities in the study
population included: chronic heart failure (n = 169), hypertension (n = 103), ischaemic heart disease (n = 102), type 2
diabetes mellitus (n = 55), renal failure (n = 43), benign prostatic hyperplasia (n = 36), lower limb atherosclerosis (n = 28),
osteoporosis (n = 19) and anaemia (n = 14).
Conclusions: Respiratory tract pathologies, such as acute exacerbation of COPD, pneumonia and lung cancer, were the
most common causes of death in the study population, while cardiovascular disease and type 2 diabetes mellitus were the
most common co-morbidities seen in these patients.
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Introduction
Chronic obstructive pulmonary disease
(COPD) is a condition characterised by a progres-
sive and poorly reversible limitation of airflow in
the respiratory tract caused by an excessive inflam-
matory response of the respiratory system to no-
xious dusts or gases (particularly to tobacco smo-
ke). It has recently been proposed to view COPD
as a systemic inflammatory disorder, as the respi-
ratory changes are accompanied by significant
extrapulmonary ones, such as cachexia, osteopo-
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Table 1. The main cause of death COPD patients
Cause of death n (%) Sex (F, M) Age at the death (years)
COPD exacerbation 81 (30%) F = 32 M = 49 73 ± 8
Pneumonia 67 (25%) F = 17 M = 50 76 ± 8*
Lung cancer 50 (19%) F = 18 M = 32 69 ± 9**
Ischaemic heart disease 20 (7%) F = 5 M = 15 74 ± 6
Heart failure 14 (5%) F = 6 M = 8 73 ± 9
*p = 0,02; **p = 0,002
rosis, loss of lean body mass, depression, anaemia
and a higher prevalence of cardiovascular disease.
The definitions of COPD contained in the Global
Initiative for Obstructive Lung Disease (GOLD)
report and the guidelines of the European Respi-
ratory Society (ERS) and the American Thoracic
Society (ATS) also emphasise the fact that COPD
is a preventable and treatable disease [1, 2]. In spite
of that, however, COPD is currently a leading cau-
se of mortality worldwide. The data from the Glo-
bal Burden of Disease Study contained in the GOLD
report indicate that COPD will have become the
third most common cause of death by 2020 com-
pared to 1990, when the disease ranked sixth in
terms of the most common causes of mortality [1].
According to the World Health Organisation
(WHO) report published in 2007, COPD was the
fifth most common cause of death worldwide. This
increase is associated with the increasing preva-
lence of smoking and population ageing. Cardio-
vascular disease, pneumonia and cancer are con-
sidered common causes of death in patients with
COPD [3, 4].
The aim of the study was to analyse the cau-
ses of death and co-morbidities in COPD patients
who had died during hospitalisation at the Depart-
ment of Internal Medicine, Pneumonology and
Allergy, Medical University of Warsaw, Poland,
between 2004 and 2008.
Material and methods
This was a retrospective study in which we
analysed 854 medical records of patients who had
died at the Department of Internal Medicine, Pneu-
monology and Allergy, Medical University of War-
saw, Poland, between 2004 and 2008. In 266 cases
(179 [67%] men and 87 [33%] women), one of the
diagnoses was COPD (ICD-10 code: J44). The mean
age at death among the patients with COPD was
73 ± 8 years 73 ± 8 years (men: 73 ± 8 years;
women: 74 ± 9 years). The cause of death was es-
tablished on the basis of the diagnosis made by the
treating physician, and the co-morbidities were
established on the basis of history, discharge re-
ports from previous hospitalisations and the inve-
stigations performed during the hospitalisation.
Results
In most of the patients from the study popula-
tion, the causes of death may be subdivided into
respiratory and cardiovascular causes. Table 1
summarises the main causes of death in the study
population by age and sex. The mean age at death
in patients who had died from lung cancer was
significantly lower from the mean age of the study
population (p = 0.002), while pneumonia was the
main cause of death in most of the older patients
(p = 0.02). In isolated cases the causes of death
were as follows: pulmonary embolism (n = 5), sto-
mach cancer (n = 2), oesophageal cancer (n = 2),
renal cancer (n = 2), cancer of unknown primary
(n = 2), renal failure (n = 3), acute respiratory fa-
ilure (n = 3), staphylococcal sepsis (n = 2), pul-
monary haemorrhage (n = 1), pneumothorax (n =
1), pneumomediastinum (n = 1), pulmonary tuber-
culosis (n = 1), pleural empyema (n = 1), intesti-
nal obstruction (n = 1), gastrointestinal haemorr-
hage (n = 2), stroke (n = 1), pulmonary fibrosis (n
= 1), chronic lymphocytic leukaemia (n = 1), lym-
phoma (n = 1) and aspiration (n = 1). The most
common co-morbidities in the study population
were cardiovascular diseases: chronic heart failu-
re, hypertension and ischaemic heart disease. Ta-
ble 2 summarises the prevalence of the most com-
mon co-morbidities in the study population. The
following co-morbidities were less common: hyper-
thyroidism (n = 8), cholelithiasis (n = 8), rheuma-
toid arthritis (n = 2) and isolated cases of a histo-
ry of cancer in various sites. Nine subjects had a
history of stroke. The causes of death in patients
receiving home oxygen therapy were analysed se-
parately. The mean age at death among these pa-
tients was 73 ± 7 years. The causes of death inc-
luded an acute exacerbation of COPD in 17 cases,
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pneumonia in 4 cases, lung cancer in 2 cases and
pulmonary embolism in 1 case.
Discussion
Chronic obstructive pulmonary disease is an
inflammatory disorder. The long-reported inflam-
mation is not, however, local and confined to the
airways: it is a systemic inflammation whose me-
diators are also responsible for the extrapulmona-
ry consequences of COPD. The commonly used
prognostic markers are FEV1 (forced expiratory
volume in one second) and the BODE index, which
takes into account body mass index (BMI), airway
obstruction (as measured by FEV1), dyspnoea (as
measured by the MRC [Medical Research Council]
dyspnoea scale) and exercise tolerance (as measu-
red by the 6-minute walk test distance) [5].
Recent studies suggest that lung cancer, mu-
scular atrophy, osteoporosis, anaemia, ischaemic
heart disease, anxiety and depression often co-exist
with COPD [6]. The causes of death in patients with
COPD reported in the literature depend on the
characteristics of the study population. In the Lung
Health Study, over the 14 years of follow-up of
5887 smokers aged 35–60 years with the diagnosis
of mild to moderate airway obstruction on spiro-
metry, the most common causes of death included
cancer (33%) and cardiovascular disease (22%)
with respiratory diseases accounting for a mere 8%
[7]. The analysis of causes of death in a group of
patients with severe COPD managed with inhaled
glucocorticosteroids shows different results: the
most common causes of death were respiratory
diseases (34%) and cardiovascular disease (30%)
with cancer occurring in 21% of the cases (most of
which were respiratory tract malignancies). In this
analysis the patients who had died from respirato-
ry causes had considerably lower FEV1 values com-
pared to the others [8]. Similar results were obta-
ined in the TORCH (Towards the Revolution in
COPD Health) study, in which respiratory diseases
accounted for 35%, cardiovascular disease for 27%
and cancer for 21% of deaths [9]. A larger number
of deaths due to respiratory causes in the group
managed with inhaled glucocorticosteroids may be
associated with a higher number of pneumonia
cases [10].
In a two-year prospective analysis conducted
by Scandinavian researchers, in a group of 416
patients hospitalised for an acute exacerbation of
COPD, the main causes of death were respiratory
complications, cardiovascular complications and
cancer. Patients who had died were characterised
by an older age, worse spirometric parameters and
worse general health. The prognosis was additio-
nally worsened by diabetes mellitus [11]. Our re-
sults are consistent with those reported in the lite-
rature. Respiratory and cardiovascular diseases
were the most common causes of death in our pa-
tients. However, the lack of complete data made it
impossible to carry out an analysis based on the
severity of the disease established on the basis of
FEV1. Most of our patients were being managed
with systemic glucocorticosteroids during hospi-
talisation. The mean age at death was 73 ± 8 years
and was significantly lower in the group of patients
who had died from lung cancer (69 ± 9 years).
Other respiratory diseases, mainly pneumonia, as
the causes of death in COPD patients are often di-
scussed. In a paper on the role of infection as the
cause of death in COPD, Sethi [12] points out to
the role of chronic bacterial infection, which — if
unsuccessfully treated with antibiotics — contri-
butes to the constant decrease in respiratory rese-
rves and forms a portal of entry for other microor-
ganisms. In their analysis of the causes of death in
patients with chronic respiratory failure on home
oxygen therapy, Zieliński et al. [13] listed the fol-
lowing as the main causes of death: acute respira-
tory failure (38%), heart failure (13%), respiratory
infections (11%), pulmonary embolism (10%), car-
diac arrhythmias (8%), lung cancer (7%). In our
study population, a total of 24 subjects had been
on home oxygen therapy and the direct causes of
death were similar: an acute exacerbation of COPD
in 17 cases, pneumonia in 4 cases, lung cancer in
2 cases and pulmonary embolism in 1 case.
Co-morbidities are a significant factor affec-
ting the general condition of COPD patients. As
already mentioned, diabetes mellitus is an impor-
tant factor affecting mortality in patients with
COPD. The three main co-morbidities of COPD in
Table 2. Comorbidities in COPD patients
Disease n K/F M/M
Chronic heart failure 169 51 118
Arterial hypertension 103 37 66
Ischaemic heart disease 102 37 65
Respiratory failure 82 28 54
Diabetes mellitus type 2 55 15 40
Lung tuberculosis in anamnesi 45 12 33
Chronic renal failure 43 10 33
Hypertrophy prostatae 36 – 36
Osteoporosis 19 10 9
Anaemia 14 2 12
Pneumonologia i Alergologia Polska 2011, vol. 79, no 5, pages 343–346
346 www.pneumonologia.viamedica.pl
our study were: chronic heart failure, hypertension
and ischaemic heart disease. These were followed
by: type 2 diabetes mellitus, peripheral artery di-
sease, osteoporosis and anaemia. These findings
are consistent with the literature [3].
Conclusions
Respiratory tract pathologies, such as acute
exacerbation of COPD, pneumonia and lung can-
cer, were the most common causes of death in the
study population, while cardiovascular disease and
type 2 diabetes mellitus were the most common co-
morbidities seen in these patients.
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